News

U.S. IPO Weekly Recap: Sizable Precision Medicine And Insurance IPOs Raise A Combined $902 Million

  • A handful of IPOs and blank checks priced in the short holiday week, led by two sizable issuers. Two smaller IPOs also priced this past week. One IPO is currently scheduled to list in the week ahead, although some small names may also join the calendar throughout the week.
    06/22/2025

Jyong Biotech Ltd. Announces Closing of $20 Million Initial Public Offering

  • New Taipei City, Taiwan, June 18, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced the closing of its initial public offering (the “Offering”) of 2,666,667 ordinary shares (the “Ordinary Shares”) at a public offering price of $7.5 per share for aggregate gross proceeds of approximately $20 million, before deducting underwriting discounts and other offering expenses. The Ordinary Shares commenced trading on Nasdaq Global Market on June 17, 2025, under the ticker symbol “MENS”. The Offering closed on June 18, 2025.
    06/18/2025
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Jyong Biotech Ltd. Ordinary Shares (MENS) can sell. Click on Rating Page for detail.

The price of Jyong Biotech Ltd. Ordinary Shares (MENS) is 10.01 and it was updated on 2025-07-12 07:00:21.

Currently Jyong Biotech Ltd. Ordinary Shares (MENS) is in undervalued.

Unlock
MENS Ratings Summary
MENS Quant Ranking